These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 10561135)

  • 1. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.
    Lewis JB; Berl T; Bain RP; Rohde RD; Lewis EJ
    Am J Kidney Dis; 1999 Nov; 34(5):809-17. PubMed ID: 10561135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
    Ruggenenti P; Perna A; Gherardi G; Garini G; Zoccali C; Salvadori M; Scolari F; Schena FP; Remuzzi G
    Lancet; 1999 Jul; 354(9176):359-64. PubMed ID: 10437863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strict blood-pressure control and progression of renal failure in children.
    ; Wühl E; Trivelli A; Picca S; Litwin M; Peco-Antic A; Zurowska A; Testa S; Jankauskiene A; Emre S; Caldas-Afonso A; Anarat A; Niaudet P; Mir S; Bakkaloglu A; Enke B; Montini G; Wingen AM; Sallay P; Jeck N; Berg U; Caliskan S; Wygoda S; Hohbach-Hohenfellner K; Dusek J; Urasinski T; Arbeiter K; Neuhaus T; Gellermann J; Drozdz D; Fischbach M; Möller K; Wigger M; Peruzzi L; Mehls O; Schaefer F
    N Engl J Med; 2009 Oct; 361(17):1639-50. PubMed ID: 19846849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
    Shigihara T; Sato A; Hayashi K; Saruta T
    Hypertens Res; 2000 May; 23(3):219-26. PubMed ID: 10821130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure.
    Wühl E; Mehls O; Schaefer F;
    Kidney Int; 2004 Aug; 66(2):768-76. PubMed ID: 15253732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome survey in unselected hypertensive patients with type 2 diabetes mellitus: effects of ACE inhibition.
    Veelken R; Delles C; Hilgers KF; Schmieder RE
    Am J Hypertens; 2001 Jul; 14(7 Pt 1):672-8. PubMed ID: 11465652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).
    Freedman BI; Wuerth JP; Cartwright K; Bain RP; Dippe S; Hershon K; Mooradian AD; Spinowitz BS
    Control Clin Trials; 1999 Oct; 20(5):493-510. PubMed ID: 10503809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics. Collaborative Study Group.
    Rodby RA; Rohde R; Evans J; Bain RP; Mulcahy WS; Lewis EJ
    J Am Soc Nephrol; 1995 Apr; 5(10):1775-81. PubMed ID: 7787145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
    Bakris GL; Weir MR; DeQuattro V; McMahon FG
    Kidney Int; 1998 Oct; 54(4):1283-9. PubMed ID: 9767545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy.
    Suzuki H; Kanno Y; Ikeda N; Nakamoto H; Okada H; Sugahara S
    Hypertens Res; 2002 Nov; 25(6):865-73. PubMed ID: 12484510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
    Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
    Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.